EP-1350 DART-bid by VMAT for locally advanced NSCLC: Low toxicity, encouraging survival and tumor control. (April 2019) - Wurstbauer, K.; Pinter, R.; Meinschad, M.; Kazil, M.; Hernler, T.; Cerkl, P.; Künzler, T.; De Vries, A.